Concepedia

Thomas Cheung Yau

TC

Statistics

Publications

9

Citations

525

H-Index

9

Active since

2012

Affiliations

University of Hong Kong(Current)

University of Southern California

Providence Portland Medical Center

Clinica Universidad de Navarra

Bristol-Myers Squibb (United States)

Thomas Cheung Yau is an author at University of Hong Kong specializing in cancer therapeutics, hepatology, and radiation oncology.

Top concepts

Publications per year

2012–2018

9

Publications

9

Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.

Anthony B. El-Khoueiry, Ignacio Melero, Todd S. Crocenzi et al. · Journal of Clinical Oncology · 2015 · 196 citations

, , +20

Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.

Todd S. Crocenzi, Anthony B. El-Khoueiry, Thomas Cheung Yau et al. · Journal of Clinical Oncology · 2017 · 86 citations

, , +21

Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040.

Anthony B. El-Khoueiry, Ignacio Melero, Thomas Cheung Yau et al. · Journal of Clinical Oncology · 2018 · 53 citations

, , +21

Safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 CheckMate-040 study.

Bruno Sangro, Ignacio Melero, Thomas Cheung Yau et al. · Journal of Clinical Oncology · 2016 · 43 citations

, , +27

Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.

Anthony B. El-Khoueiry, Ignacio Melero, Todd S. Crocenzi et al. · Journal of Clinical Oncology · 2015 · 41 citations

, , +18

1–5 of 9